Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma

Mini Rev Med Chem. 2023 Sep 15. doi: 10.2174/1389557523666230915103121. Online ahead of print.ABSTRACTLymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NHL, especially in diffuse large B cell lymphoma (DLBCL), central nerve cell lymphoma, and follicular lymphoma. The technologies discussed include clinical imaging, targeted drug delivery, photodynamic therapy (PDT), and thermodynamic therapy for lymphoma. This review aims to provide a better understanding of the use of nanotechnology in the treatment of non-Hodgkin's lymphoma.PMID:37724679 | DOI:10.2174/1389557523666230915103121
Source: Mini Reviews in Medicinal Chemistry - Category: Chemistry Authors: Source Type: research